![]() Many insurers now seek to stop patients from counting manufacturer coupons as part of their cost-sharing obligations, the groups alleged in their complaint. “We trust the court will side with us-and invalidate the ability to implement these punitive practices that impact people with HIV, hepatitis, and so many other health conditions that are treated with prescription drugs,” Schmid added. The groups filed the complaint Tuesday in the US District Court for the District of Columbia. “This practice is not only illegal but increases the cost of prescription drugs for millions of patients nationwide,” Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in a statement. The HIV+Hepatitis Policy Institute, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition allege the policy has allowed insurance companies and pharmacy benefit managers-the entities that manage prescription drug benefits on behalf of insurers-to collect funds from both patients and drugmakers while not using any of that money to alleviate the financial burden on patients. The rule (RIN: 0938-AT98) was issued in 2020 by the Centers for Medicare & Medicaid Services and says health insurers don’t have to count copay assistance from drugmakers toward a patient’s annual limitation on out-of-pocket costs. ![]() The complaint, obtained by Bloomberg Law, alleges the rule conflicts with the definition of “cost-sharing” in the Affordable Care Act and federal regulations. ![]() Three patient advocacy groups are suing the Biden administration over a Trump-era rule that they argue has allowed insurers and pharmacy benefit managers to increase out-of-pocket prescription drug costs for consumers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |